Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

NCT05640830 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Advanced Gastric Cancer

Interventions

DRUG: trastuzumab, bevacizumab with paclitaxel (triple combination)

Sponsor

Kangbuk Samsung Hospital